Europe Pharmacogenetics Testing in PsychiatryDepression Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	565 Pages	Data Bridge Market Research	February, 2024	DAABD18636649

Best Price Guarantee
Price	from $3,500
Length	565 Pages
Publisher	Data Bridge Market Research
Published Date	February, 2024
SKU	DAABD18636649

Europe Pharmacogenetics Testing in PsychiatryDepression Market

Europe pharmacogenetics testing in psychiatry/depression market is expected to reach USD 801.80 thousand by 2031 from USD 383.56 thousand in 2023, growing with a CAGR of 9.9% in the forecast period of 2024 to 2034.

Market Segmentation

Europe Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing and Chromosomal Array-Based Tests), Patient Type (Child, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software and Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others), Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

Driver
• Rising number of population suffering from depressive disorder

Restraint
• Insufficient clinical validation

Opportunity
• Advancements in genetic testing

Market Players

Some of the major market players operating in the Europe pharmacogenetics testing in psychiatry/depression market are listed below:
• ThermoFisher Scientific Inc. (U.S.)
• Illumina Inc. (U.S.)
• Myriad Genetics Inc. (U.S.)
• Sonic Healthcare Limited (Australia)
• QIAGEN (Germany)
• AB-BIOTICS S.A. (Spain)
• BiogeniQ Inc. (Canada)
• Castle Bioscience Inc. (U.S.)
• Coriell Life Sciences (U.S.)
• Dynamic DNA Laboratories (U.S.)
• Eurofins Scientific (Luxembourg)
• Genelex (U.S.)
• Genewiz (U.S.)
• Genomind Inc. (U.S.)
• GenXys (Canada)
• HealthSpek (U.S.)
• HudsonAlpha (U.S.)
• MD Labs (U.S.)
• ONEOME LLC (U.S.)
• PacBio (U.S.)

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of Europe Pharmacogenetics Testing In Psychiatry/Depression Market; 1.4 Currency And Pricing; 1.5 Limitations; 1.6 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Dbmr Tripod Data Validation Model; 2.5 Primary Interviews With Key Opinion Leaders; 2.6 Multivariate Modelling; 2.7 Market End User Coverage Grid; 2.8 Type Lifeline Curve; 2.9 Dbmr Market Position Grid; 2.10 Vendor Share Analysis; 2.11 Secondary Sources; 2.12 Assumptions
3 Executive Summary
4 Premium Insight: 4.1 Pestal Analysis; 4.2 Porters Five Forces
5 Industrial Insights
6 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, Regulations: 6.1 U.S.; 6.2 European Union (Eu); 6.3 France; 6.4 Australia; 6.5 South Korea
7 Market Overview: 7.1 Drivers; 7.1.1 Rising Number Of Population Suffering From Depressive Disorder; 7.1.2 Initiatives Taken By Manufacturers Due To Genetic Variability; 7.1.3 Growing Biotechnology Sector Along With Rising Healthcare Expenditure; 7.1.4 Increasing Interest For Personalized And Precision Medication; 7.2 Restraints; 7.2.1 Insufficient Clinical Validation; 7.2.2 Stigma And Perception For Mental Health; 7.2.3 Lack Of Reimbursement; 7.3 Opportunities; 7.3.1 Advancements In Genetic Testing; 7.3.2 Emerging Start-ups Branches Innovation; 7.3.3 Reduced Healthcare Costs Through The Implementation Of Cost-saving Measures; 7.4 Challenges; 7.4.1 Rising Concern Regarding Data Privacy And Security; 7.4.2 Shortage Of Skilled Healthcare Professionals
8 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Product: 8.1 Overview; 8.2 Consumables; 8.3 Instruments; 8.4 Software And Services
9 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type: 9.1 Overview; 9.2 Whole Genome Sequencing; 9.3 Chromosomal Array Based Tests
10 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Type: 10.1 Overview; 10.2 Anxiety; 10.3 Depression; 10.4 Mood Disorders; 10.5 Bipolar Disorders; 10.6 Eating Disorders; 10.7 Psychotic Disorders
11 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type: 11.1 Overview; 11.2 Cyp2c19; 11.3 Cyp2c9 And Vkorc1; 11.4 Cyp2d6; 11.5 Hla-b; 11.6 Htr2a/C; 11.7 Hla-a; 11.8 Cyp3a4; 11.9 Slc6a4; 11.10 Mthfr; 11.11 Comt; 11.12 Others
12 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type: 12.1 Overview; 12.2 Adult; 12.3 Geriatric; 12.4 Child
13 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By End User: 13.1 Overview; 13.2 Hospital And Clinics; 13.3 Diagnostics Laboratories; 13.4 Academic And Research Institutes; 13.5 Others
14 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel: 14.1 Overview; 14.2 Direct Tender; 14.3 Third Party Distribution; 14.4 Hospital Pharmacy; 14.5 Others
15 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Region: 15.3 Europe; 15.3.1 Germany; 15.3.2 France; 15.3.3 U.K.; 15.3.4 Italy; 15.3.5 Russia; 15.3.6 Spain; 15.3.7 Turkey; 15.3.8 Netherlands; 15.3.9 Switzerland; 15.3.10 Poland; 15.3.11 Hungary; 15.3.12 Austria; 15.3.13 Norway; 15.3.14 Ireland; 15.3.15 Lithuania; 15.3.16 Rest Of Europe
16 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Company Landscape: 16.3 Company Share Analysis: Europe
17 Swot Analysis
18 Company Profiles: 18.1 Thermo Fisher Scientific Inc.; 18.1.1 Company Snapshot; 18.1.2 Recent Financials; 18.1.3 Company Share Analysis; 18.1.4 Product Portfolio; 18.1.5 Recent Development; 18.2 Illumina, Inc.; 18.2.1 Company Snapshot; 18.2.2 Revenue Analysis; 18.2.3 Company Share Analysis; 18.2.4 Product Portfolio; 18.2.5 Recent Developments; 18.3 Myriad Genetics, Inc.; 18.3.1 Company Snapshot; 18.3.2 Revenue Analysis; 18.3.3 Company Share Analysis; 18.3.4 Product Portfolio; 18.3.5 Recent Developments; 18.4 Sonic Healthcare Limited; 18.4.1 Company Snapshot; 18.4.2 Revenue Analysis; 18.4.3 Company Share Analysis; 18.4.4 Product Portfolio; 18.4.5 Recent Development; 18.5 Qiagen; 18.5.1 Company Snapshot; 18.5.2 Revenue Analysis; 18.5.3 Company Share Analysis; 18.5.4 Product Portfolio; 18.5.5 Recent Developments; 18.6 Ab-biotics, S.A.; 18.6.1 Company Snapshot; 18.6.2 Product Portfolio; 18.6.3 Recent Developments; 18.7 Biogeniq Inc.; 18.7.1 Company Snapshot; 18.7.2 Product Portfolio; 18.7.3 Recent Development; 18.8 Castle Bioscience, Inc.; 18.8.1 Company Snapshot; 18.8.2 Revenue Analysis; 18.8.3 Product Portfolio; 18.8.4 Recent Developments; 18.9 Coriell Life Sciences; 18.9.1 Company Snapshot; 18.9.2 Product Portfolio; 18.9.3 Recent Developments; 18.10 Dynamic Dna Laboratories; 18.10.1 Company Snapshot; 18.10.2 Product Portfolio; 18.10.3 Recent Development; 18.11 Eurofins Scientific; 18.11.1 Company Snapshot; 18.11.2 Revenue Analysis; 18.11.3 Product Portfolio; 18.11.4 Recent Developments; 18.12 Genelex (Subsiadiary Of Invitae Corporation.); 18.12.1 Company Snapshot; 18.12.2 Revenue Analysis; 18.12.3 Product Portfolio; 18.12.4 Recent Development; 18.13 Genewiz (Part Of Azenta Life Sciences); 18.13.1 Company Snapshot; 18.13.2 Revenue Analysis; 18.13.3 Product Portfolio; 18.13.4 Recent Development; 18.14 Genomind, Inc.; 18.14.1 Company Snapshot; 18.14.2 Product Portfolio; 18.14.3 Recent Developments; 18.15 Genxys; 18.15.1 Company Snapshot; 18.15.2 Product Portfolio; 18.15.3 Recent Developments; 18.16 Healthspek; 18.16.1 Company Snapshot; 18.16.2 Product Portfolio; 18.16.3 Recent Development; 18.17 Hudsonalpha; 18.17.1 Company Snapshot; 18.17.2 Product Portfolio; 18.17.3 Recent Development; 18.18 Md Labs; 18.18.1 Company Snapshot; 18.18.2 Product Portfolio; 18.18.3 Recent Development; 18.19 Oneome, Llc; 18.19.1 Company Snapshot; 18.19.2 Product Portfolio; 18.19.3 Recent Developments 556; 18.20 Pacbio; 18.20.1 Company Snapshot; 18.20.2 Revenue Analysis; 18.20.3 Product Portfolio; 18.20.4 Recent Developments
19 Questionnaire
20 Related Reports
List Of Tables: Table 1 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 2 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 3 Europe Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 4 Europe Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 5 Europe Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 6 Europe Instruments In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 7 Europe Software And Services In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 8 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 9 Europe Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 10 Europe Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 11 Europe Exome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 12 Europe Karyotype In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 13 Europe Low Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 14 Europe Deep Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 15 Europe Microarray In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 16 Europe Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 17 Europe Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 18 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Type, 2022-2031 (Usd Thousand); Table 19 Europe Anxiety In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 20 Europe Depression In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 21 Europe Mood Disorders In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 22 Europe Bipolar Disorders In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 23 Europe Eating Disorders In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 24 Europe Psychotic Disorders In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 25 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type, 2022-2031 (Usd Thousand); Table 26 Europe Cyp2c19 In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 27 Europe Cyp2c9 And Vkorc1 In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 28 Europe Cyp2d6 In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 29 Europe Hla-b In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 30 Europe Htr2a/C In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 31 Europe Hla-a In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 32 Europe Cyp3a4 In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 33 Europe Slc6a4 In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 34 Europe Mthfr In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 35 Europe Comt In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 36 Europe Others In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 37 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type, 2022-2031 (Usd Thousand); Table 38 Europe Adult In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 39 Europe Geriatric In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 40 Europe Child In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 41 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 42 Europe Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 43 Europe Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 44 Europe Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 45 Europe Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 46 Europe Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 47 Europe Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 48 Europe Others In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 49 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 50 Europe Direct Tender In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 51 Europe Third Party Distribution In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 52 Europe Hospital Pharmacy In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 53 Europe Others In Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 54 Europe Pharmacogenetics Testing In Psychiatry/Depression Market, By Region, 2022-2031 (Usd Thousand); Table 55 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Country, 2022-2031 (Usd Thousand); Table 56 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Type, 2022-2031 (Usd Thousand); Table 57 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 58 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 59 North America Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 60 North America Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 61 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 62 North America Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 63 North America Exome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 64 North America Karyotype In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 65 North America Low Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 66 North America Deep Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 67 North America Microarray In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 68 North America Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 69 North America Pharmacogenetics Testing In Psychiatry/Depression Market, Gene Type, 2022-2031 (Usd Thousand); Table 70 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type, 2022-2031 (Usd Thousand); Table 71 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 72 North America Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 73 North America Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 74 North America Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 75 North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 76 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Type, 2022-2031 (Usd Thousand); Table 77 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 78 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 79 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 80 U.S. Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 81 U.S. Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 82 U.S. Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 83 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 84 U.S. Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 85 U.S. Exome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 86 U.S. Karyotype In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 87 U.S. Low Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 88 U.S. Deep Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 89 U.S. Microarray In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 90 U.S. Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 91 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, Gene Type, 2022-2031 (Usd Thousand); Table 92 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type, 2022-2031 (Usd Thousand); Table 93 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 94 U.S. Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 95 U.S. Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 96 U.S. Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 97 U.S. Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 98 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Type, 2022-2031 (Usd Thousand); Table 99 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 100 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 101 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 102 Canada Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 103 Canada Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 104 Canada Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 105 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 106 Canada Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 107 Canada Exome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 108 Canada Karyotype In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 109 Canada Low Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 110 Canada Deep Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 111 Canada Microarray In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 112 Canada Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 113 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, Gene Type, 2022-2031 (Usd Thousand); Table 114 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type, 2022-2031 (Usd Thousand); Table 115 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 116 Canada Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 117 Canada Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 118 Canada Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 119 Canada Pharmacogenetics Testing In Psychiatry/Depression Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 120 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Type, 2022-2031 (Usd Thousand); Table 121 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 122 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 123 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 124 Mexico Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 (Usd Thousand); Table 125 Mexico Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Volume (Units); Table 126 Mexico Consumables In Pharmacogenetics Testing In Psychiatry/Depression Market, By Product, 2022-2031 Asp (Usd); Table 127 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 128 Mexico Whole Genome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 129 Mexico Exome Sequencing In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 130 Mexico Karyotype In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 131 Mexico Low Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 132 Mexico Deep Coverage Wgs In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 133 Mexico Microarray In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 134 Mexico Chromosomal Array Based Tests In Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type, 2022-2031 (Usd Thousand); Table 135 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, Gene Type, 2022-2031 (Usd Thousand); Table 136 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type, 2022-2031 (Usd Thousand); Table 137 Mexico Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 138 Mexico Hospital And Clinics In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 139 Mexico Diagnostics Laboratories In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand); Table 140 Mexico Academic And Research Institutes In Pharmacogenetics Testing In Psychiatry/Depression Market, By End User, 2022-2031 (Usd Thousand)
List Of Figures: Figure 1 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Segmentation 70; Figure 2 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Data Triangulation 73; Figure 3 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Droc Analysis 74; Figure 4 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Europe Vs Regional Market Analysis 75; Figure 5 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Company Research Analysis 75; Figure 6 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Interview Demographics 76; Figure 7 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Market End User Coverage Grid 78; Figure 8 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Dbmr Market Position Grid 80; Figure 9 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Vendor Share Analysis 82; Figure 10 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: Segmentation 86; Figure 11 North America Is Anticipated To Dominate And Asia-pacific E Is Estimated To Be Growing With The Highest Cagr In The Europe Pharmacogenetics Testing In Psychiatry/Depression Market From 2024 To 2031 87; Figure 12 The Increasing Adoption Of Pharmacogenetics Testing In Psychiatry/Depression Devices And Procedures And Rising Preference For Non-surgical Procedures Are Driving The Growth Of The Europe Pharmacogenetics Testing In Psychiatry/Depression Market In The Forecast Period Of 2024 To 2031 88; Figure 13 Anxiety Segment Is Expected To Account For The Largest Share Of The Europe Pharmacogenetics Testing In Psychiatry/Depression Market In 2024 And 2031 88; Figure 14 Asia-pacific Is The Fastest Growing Market For Europe Pharmacogenetics Testing In Psychiatry/Depression Manufacturers In The Forecast Period Of 2024 To 2031 89; Figure 15 Drivers, Restraints, Opportunities, And Challenges Of The Europe Pharmacogenetic Testing In Psychiatry/Depression Market 97; Figure 16 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Product, 2023 107; Figure 17 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Product, 2024-2031 (Usd Thousand) 108; Figure 18 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Product, Cagr (2024-2031) 108; Figure 19 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Product, Lifeline Curve 109; Figure 20 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Test Type, 2023 116; Figure 21 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Test Type, 2024-2031 (Usd Thousand) 117; Figure 22 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Test Type, Cagr (2024-2031) 117; Figure 23 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Test Type, Lifeline Curve 118; Figure 24 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Type, 2023 126; Figure 25 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Type, 2024-2031 (Usd Thousand) 127; Figure 26 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Type, Cagr (2024-2031) 127; Figure 27 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Type, Lifeline Curve 128; Figure 28 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Gene Type, 2023 137; Figure 29 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Gene Type, 2024-2031 (Usd Thousand) 138; Figure 30 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Gene Type, Cagr (2024-2031) 138; Figure 31 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Gene Type, Lifeline Curve 139; Figure 32 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Patient Type, 2023 153; Figure 33 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Patient Type, 2024-2031 (Usd Thousand) 154; Figure 34 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Patient Type, Cagr (2024-2031) 154; Figure 35 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Patient Type, Lifeline Curve 155; Figure 36 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By End User, 2023 161; Figure 37 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By End User, 2024-2031 (Usd Thousand) 162; Figure 38 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By End User, Cagr (2024-2031) 162; Figure 39 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By End User, Lifeline Curve 163; Figure 40 Europe Pharmacogenetics Testing In Psychiatry/Depression Market: By Distribution Channel, 2023 170